The Singapore International Commercial Court at the request of Novo Nordisk ordered the freezing of the worldwide assets of ...

Q4 2024 Earnings Call Transcript February 13, 2025 Vanda Pharmaceuticals Inc. beats earnings expectations. Reported EPS is ...

Q4 2024 total revenues of $53.2 million, +17% compared to Q4 2023 Q4 2024 Fanapt® net product sales of $26.6 million, +18% compared to Q4 2023 Full year 2024 total ...

Some workers are willing to trade vacation days or go back to the office in exchange for weight-loss drug coverage by their ...

A new study has found that semaglutide — the active substance in Ozempic and Wegovy — may help reduce alcohol cravings in people with AUD. Despite the availability of treatment options ...

Weight-loss drugs are increasingly popular among employees but weigh heavily on health-insurance budgets. Popular weight-loss drugs such as Ozempic, Wegovy and Zepbound are a growing factor in ...

For customers using a telehealth website to get cheaper versions of popular obesity drugs, the low prices turned out to be too good to be true. Customers of Zappy Health tell NPR they were drawn ...

Stagflation is a mix of low output, high unemployment and stubbornly rising prices that can inflict damage on businesses and ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

GLP-1 drugs — which include Ozempic and its sister drug Wegovy, as well as Mounjaro and Zepbound — mimic at least one hormone produced by the gut to signal fullness, leading to a reduced appetite.